Parexel

UCB inks strategic partnerships with Parexel, PRA

Monday, November 28, 2011 08:00 AM

The sponsor-CRO strategic partnerships just keep coming. 

More... »

PAREXEL advances early phase research technology

Tuesday, November 22, 2011 11:55 AM

More... »

Survey: Industry using medical imaging metrics to meet study milestones

Monday, November 21, 2011 09:09 AM

Boston-based Perceptive Informatics, an eClinical solutions provider and a subsidiary of CRO Parexel International, found in a global survey that over half (54%) of respondents review medical imaging-related study metrics on a regular basis. Of those respondents, 81% use medical imaging metrics as actionable data to inform progress toward the achievement of study milestones. Key performance indicators used by the respondents include the status of site qualification for imaging-based clinical trials, as well as progress of medical image submissions, query responses and radiology reviews.

More... »

UCB enters strategic partnerships with Parexel and PRA

Thursday, November 17, 2011 10:33 AM

Brussels, Belgium-based UCB has entered into strategic partnerships with Parexel and PRA to drive UCB’s operational clinical development activities. The agreements are effective for all of UCB’s new clinical study programs on a global basis.

More... »

U.K.’s MRN brings its home services for patients to U.S. market, predicting big growth in clinical trials use

Monday, November 14, 2011 08:02 AM

U.K.-based Medical Research Network (MRN), a five-year-old company that arranges for clinical trial participants to be seen in their homes rather than requiring them to travel to an investigative site, recently announced it is establishing a presence in the U.S. via a new office in Raleigh, N.C. 

More... »

Survey: 80% of big pharma companies restructuring to strategically outsource more trials to CROs

Monday, October 31, 2011 08:00 AM

According to a recent survey from William Blair, about 80% of big pharma companies either are in the process of restructuring or have already completed restructuring plans to strategically outsource more of their trials to CROs.

More... »

Parexel expands commercialization services

Thursday, October 27, 2011 01:14 PM

Parexel International has expanded its capabilities to provide biopharmaceutical companies with dedicated support for their commercialization goals.  PAREXEL has fully integrated its commercialization services to help clients maximize regional and global market access opportunities. These solutions align reimbursement strategies with clinical development to gather the precise data required to demonstrate product value.

More... »

Survey: Top CROs doubled workforce over past decade

Monday, October 24, 2011 08:02 AM

Over the last 10 years, the top nine global CROs have more than doubled their workforce, which now exceeds 72,000 employees, and their revenues have increased at a compound annualized rate of 11% as they increasingly play a larger and more integral role in the drug development infrastructure, according to a new Association of Clinical Research Organizations (ACRO) member survey.

More... »

PAREXEL Academy expands to Singapore

Tuesday, October 11, 2011 01:11 PM

PAREXEL Academy, a provider of education and professional training for the biopharmaceutical industry in the field of clinical research, which is operated by PAREXEL International, has entered into an agreement with the National University of Singapore (NUS), through its National University of Singapore Academy of GxP Excellence (NUSAGE), to offer an academic program in Singapore to help meet the increasing demand for talent in the field of clinical research in the Asia region. This demand is being driven by the growing complexity and globalization of biopharmaceutical research and development.

More... »

CROs using backlog numbers to put positive spin on less-than-stellar quarterly earnings reports

Monday, August 22, 2011 08:00 AM

Using backlog allows CROs to put a positive spin on what otherwise might be less-than-stellar earnings; while they may not have had the healthiest quarter—or year—financially, they can showcase all of the work that has been promised over the next few quarters in millions, or billions, of dollars.

More... »